| Name | Walgreens #7310 |
|---|---|
| Organization Name | Walgreen Co |
| Location | 799 Louis Henna Blvd, Round Rock, Texas 78664 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (512) 310-7678 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Researchers studying strategies to develop a non-hormonal approach to male contraception have reached an important milestone in their work, discovering a way to produce a key enzyme found only in sperm in sufficient quantities that they can begin designing drugs to stop the sperm from swimming to the egg.
Using gene chips to profile tumors before treatment, researchers at Harvard and Yale Universities found markers that identified breast cancer subtypes resistant to Herceptin, the primary treatment for HER2-positive breast cancer. They say this advance could help further refine therapy for the 25 to 30 percent of breast cancer patients with this class of tumor.
The Multiple Myeloma Research Foundation (MMRF) applauded today's Celgene announcement regarding Revlimid, a new class of novel immunomodulatory drugs currently being evaluated to treat a broad range of hematology and oncology conditions, including multiple myeloma.
Neurocrine Biosciences, Inc. announced today that it has recently completed subject randomization of the Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Mono-Amine Transporter 2 (VMAT2) compound NBI-98854 in tardive dyskinesia patients.
› Verified 5 days ago
| NPI Number | 1396750451 |
| Organization Name | WALGREEN CO |
| Doing Business As | WALGREENS #07310 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 799 Louis Henna Blvd, Round Rock, TX 78664 |
| Phone Number | 512-310-7678 |
News Archive
Researchers studying strategies to develop a non-hormonal approach to male contraception have reached an important milestone in their work, discovering a way to produce a key enzyme found only in sperm in sufficient quantities that they can begin designing drugs to stop the sperm from swimming to the egg.
Using gene chips to profile tumors before treatment, researchers at Harvard and Yale Universities found markers that identified breast cancer subtypes resistant to Herceptin, the primary treatment for HER2-positive breast cancer. They say this advance could help further refine therapy for the 25 to 30 percent of breast cancer patients with this class of tumor.
The Multiple Myeloma Research Foundation (MMRF) applauded today's Celgene announcement regarding Revlimid, a new class of novel immunomodulatory drugs currently being evaluated to treat a broad range of hematology and oncology conditions, including multiple myeloma.
Neurocrine Biosciences, Inc. announced today that it has recently completed subject randomization of the Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Mono-Amine Transporter 2 (VMAT2) compound NBI-98854 in tardive dyskinesia patients.
› Verified 5 days ago
News Archive
Researchers studying strategies to develop a non-hormonal approach to male contraception have reached an important milestone in their work, discovering a way to produce a key enzyme found only in sperm in sufficient quantities that they can begin designing drugs to stop the sperm from swimming to the egg.
Using gene chips to profile tumors before treatment, researchers at Harvard and Yale Universities found markers that identified breast cancer subtypes resistant to Herceptin, the primary treatment for HER2-positive breast cancer. They say this advance could help further refine therapy for the 25 to 30 percent of breast cancer patients with this class of tumor.
The Multiple Myeloma Research Foundation (MMRF) applauded today's Celgene announcement regarding Revlimid, a new class of novel immunomodulatory drugs currently being evaluated to treat a broad range of hematology and oncology conditions, including multiple myeloma.
Neurocrine Biosciences, Inc. announced today that it has recently completed subject randomization of the Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Mono-Amine Transporter 2 (VMAT2) compound NBI-98854 in tardive dyskinesia patients.
› Verified 5 days ago
Blue Sky Orthotic And Prosthetics Type: Prosthetic/Orthotic Supplier Location: 3141 Eagles Nest St, Round Rock, Texas 78665 Phone: (512) 761-3646 | |
Cvs Pharmacy #00116 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2001 E Palm Valley Blvd, Round Rock, Texas 78665 Phone: (512) 244-1069 | |
Cvs Pharmacy #00928 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 800 W Old Settlers Blvd, Round Rock, Texas 78681 Phone: (512) 255-1331 | |
Cvs Pharmacy #02368 Type: Medicare Supplier Location: 7001 Wyoming Springs, Round Rock, Texas 78681 Phone: (512) 716-0757 | |
Cvs Pharmacy #06690 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 501 University Blvd, Round Rock, Texas 78665 Phone: (512) 310-8791 |